UP­DAT­ED: Make that 2 ap­proved RNAi drugs at Al­ny­lam af­ter the FDA of­fers a speedy OK on ul­tra-rare dis­ease drug

5 hours ago
R&D

Stephen Hahn gets through Sen­ate’s soft­ball job in­ter­view — but most­ly plays dodge­ball on the is­sues fac­ing the FDA

5 hours ago
Bioregnum

Ac­tivist in­vestor wages suit on On­coSec over re­cent deal; Breast can­cer ex­perts de­but biotech with $12M seed

6 hours ago
Protocols

Op­di­vo/Yer­voy com­bo for melanoma fails in key pa­tient pop­u­la­tion

7 hours ago
R&D

Eli Lil­ly touts $400M man­u­fac­tur­ing ex­pan­sion, 100 new jobs to much fan­fare in In­di­anapo­lis — even though it's been chop­ping staff

7 hours ago
Pharma

Ver­tex's stel­lar quar­ter car­ries on with French re­im­burse­ment deal

8 hours ago
R&D

Kymera hands the helm to No­var­tis vet — and found­ing CSO — Nel­lo Main­olfi

8 hours ago
R&D

MPM and Long­wood-backed Were­wolf Ther­a­peu­tics grabs $56 mil­lion to take tu­mors by night

10 hours ago
Venture

UP­DAT­ED: Lon­don's bio­phar­ma-fo­cused GHO Cap­i­tal Part­ners claims close of largest-ever Eu­ro­pean fund

10 hours ago
Venture

Am­gen chops 172 more staffers in R&D, op­er­a­tions and sales amid neu­ro­science ex­it, rev­enue down­turn

10 hours ago
People

Ab­b­Vie lines up a new pre­clin­i­cal R&D al­liance with the deal­mak­ers at nat­ur­al killer play­er Drag­on­fly

10 hours ago
R&D

With eyes on a poly­mer em­pire prize, French medtech play­er seals $42M in fresh fund­ing

23 hours ago
Startups

As­traZeneca los­es an­oth­er ex­ec­u­tive to biotech, as Badrul Chowd­hury moves to Savara

Yesterday
People
Pharma

Alk­er­mes sub­mits long await­ed NDA for schiz­o­phre­nia, bipo­lar drug; Is a uni­corn bub­ble drag­ging the IPO mar­ket?

Yesterday
Protocols

No­var­tis is eye­ing a multi­bil­lion-dol­lar Med­Co buy­out as Jer­sey biotech nears NDA — re­ports

Yesterday
R&D

Lon­don AI up­start, which counts No­var­tis as a cus­tomer, can teach your com­put­er to read

Yesterday
R&D

Here's a $25M seed fund aimed at back­ing some brash new drug ideas out of the Broad

Yesterday
Discovery
Venture

Welling­ton lines up a $393M bankroll for its next round of pri­vate biotech bets — and they’re like­ly think­ing big

Yesterday
R&D

As uter­ine race with Ab­b­Vie heats up, My­ovant eyes FDA ap­proval with tri­al re­sults from prostate can­cer

Yesterday
R&D

UP­DAT­ED: In a land­mark first glimpse of hu­man da­ta from Ver­tex, CRISPR/Cas9 gene ther­a­py sig­nals ear­ly ben­e­fit

Yesterday
Cell/Gene Tx
R&D

Supreme Court turns down Mar­tin Shkre­li's lat­est ap­peal, leav­ing 'phar­ma bro' to 7-year sen­tence

Yesterday
People

Eliz­a­beth War­ren pro­pos­es us­ing com­pul­so­ry li­cens­ing, an­titrust ac­tions to break bio­phar­ma’s con­trol of drug pric­ing — and here are the block­busters she’s tar­get­ing first

2 days ago
Bioregnum
Pharma

In rare po­lit­i­cal for­ay, top biotech in­vestors urge Con­gress to re­ject drug pric­ing bill

2 days ago
R&D

Dicer­na scores broad, 'rest of liv­er' deal with No­vo Nordisk, bag­ging $225M in cash to hit some 30 tar­gets with RNAi plat­form

2 days ago
Deals
1234 Next page Last page